Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has granted stock options to two new employees. The grants, approved by the Compensation Committee, total 60,000 shares under the company's 2022 Inducement Plan.
The options have a 10-year term with an exercise price of $10.21 per share, matching Nasdaq's reported sale price on December 2, 2024. The vesting schedule includes 25% after one year, with the remaining 75% vesting monthly over three years, contingent on continued employment.
Olema Pharmaceuticals (Nasdaq: OLMA), una società biofarmaceutica in fase clinica focalizzata su terapie mirate per il tumore al seno, ha concesso opzioni su azioni a due nuovi dipendenti. Le concessioni, approvate dal Comitato per la Compensazione, ammontano a un totale di 60.000 azioni nell'ambito del Piano di Induzione 2022 della società.
Le opzioni hanno un termine di 10 anni con un prezzo di esercizio di $10,21 per azione, corrispondente al prezzo di vendita riportato da Nasdaq il 2 dicembre 2024. Il programma di maturazione prevede un 25% dopo un anno, con il restante 75% che matura mensilmente su un periodo di tre anni, subordinato al mantenimento dell'impiego.
Olema Pharmaceuticals (Nasdaq: OLMA), una empresa biofarmacéutica en etapa clínica enfocada en terapias específicas para el cáncer de mama, ha otorgado opciones sobre acciones a dos nuevos empleados. Las concesiones, aprobadas por el Comité de Compensación, totalizan 60,000 acciones bajo el Plan de Inducción 2022 de la empresa.
Las opciones tienen un plazo de 10 años con un precio de ejercicio de $10.21 por acción, coincidiendo con el precio de venta reportado por Nasdaq el 2 de diciembre de 2024. El cronograma de adquisición incluye un 25% después de un año, con el 75% restante adquiriendo mensual durante tres años, sujeto a la continuidad del empleo.
올레마 제약 (Nasdaq: OLMA)는 유방암에 대한 표적 치료에 중점을 둔 임상 단계의 생명공학 회사로, 두 명의 새로운 직원에게 주식 옵션을 부여했습니다. 이러한 지급은 보상 위원회에서 승인되었으며, 2022 유인 계획에 따라 총 60,000주입니다.
옵션은 10년의 기간을 가지며, 행사 가격은 주당 $10.21로, 2024년 12월 2일 Nasdaq에서 보고된 판매 가격과 일치합니다. 수익 일정은 1년 후 25%가 베스팅되며, 남은 75%는 3년에 걸쳐 매달 베스팅되며, 지속적인 고용에 따라 다릅니다.
Olema Pharmaceuticals (Nasdaq: OLMA), une entreprise bio-pharmaceutique en phase clinique spécialisée dans les thérapies ciblées pour le cancer du sein, a accordé des options d'achat d'actions à deux nouveaux employés. Les attributions, approuvées par le Comité de Compensation, totalisent 60 000 actions dans le cadre du Plan d'Incitation 2022 de l'entreprise.
Les options ont une durée de 10 ans avec un prix d'exercice de 10,21 $ par action, correspondant au prix de vente rapporté par Nasdaq le 2 décembre 2024. Le calendrier d'acquisition comprend 25 % après un an, le 75 % restant s'acquérant mensuellement sur trois ans, sous réserve de la continuité de l'emploi.
Olema Pharmaceuticals (Nasdaq: OLMA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf gezielte Therapien gegen Brustkrebs konzentriert, hat zwei neuen Mitarbeitern Aktienoptionen gewährt. Die Zuteilungen, die vom Vergütungsausschuss genehmigt wurden, belaufen sich auf insgesamt 60.000 Aktien im Rahmen des Unternehmensplans zur Einführung von 2022.
Die Optionen haben eine Zeitraum von 10 Jahren mit einem Ausübungspreis von $10,21 pro Aktie, was dem von Nasdaq am 2. Dezember 2024 gemeldeten Verkaufspreis entspricht. Der Vesting-Zeitplan sieht vor, dass 25 % nach einem Jahr und die verbleibenden 75 % über drei Jahre monatlich fällig werden, abhängig von der weiteren Beschäftigung.
- None.
- None.
SAN FRANCISCO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 60,000 shares of the Company's common stock, effective as of December 2, 2024. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
What is the exercise price of Olema Pharmaceuticals' (OLMA) December 2024 stock option grants?
How many shares were included in Olema Pharmaceuticals' (OLMA) December 2024 inducement grants?
What is the vesting schedule for Olema Pharmaceuticals' (OLMA) December 2024 stock option grants?
